Montelukast for symptom control of interstitial cystitis

Jamie L. Traut, Erin S. MacDonald, Mikayla L. Spangler, Shailendra Saxena

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVE: To describe the effects of montelukast, a leukotriene receptor antagonist commonly used in the treatment of allergic rhinitis and asthma, on the symptoms of interstitial cystitis (IC). CASE SUMMARY: A 64-year-old male had a history of IC with previous trials of solifenacin, dutasteride, and tamsulosin and little improvement in IC symptom reduction. When montelukast 10 mg was initiated for allergic rhinitis symptoms, a substantial improvement in urinary urgency and pain during therapy was noted. This improvement subsequently disappeared when montelukast was stopped. DISCUSSION: IC, a rare occurrence in the male population, is related to an inflammatory process and has also been associated with inappropriate leukotriene release, which is the target of montelukast therapy. In general, treatment for IC includes systemic medical therapy, local bladder treatment, surgical and neurosurgical procedures, and intravesical drug installation. Currently, montelukast is Food and Drug Administration approved for use in the treatment and prevention of mild-to-moderate asthma and exercise-induced asthma, as well as treatment of seasonal and perennial allergic rhinitis. While montelukast treatment did not cure the patient's IC, it improved his quality of life through substantial symptomatic relief, including less pain and urgency. CONCLUSIONS: Montelukast may be an effective treatment option in the management of interstitial cystitis. Further research is needed to substantiate this novel use.

Original languageEnglish
JournalAnnals of Pharmacotherapy
Volume45
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

montelukast
Interstitial Cystitis
Therapeutics
tamsulosin
Asthma
Exercise-Induced Asthma
Neurosurgical Procedures
Leukotriene Antagonists
Pain
Seasonal Allergic Rhinitis

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Montelukast for symptom control of interstitial cystitis. / Traut, Jamie L.; MacDonald, Erin S.; Spangler, Mikayla L.; Saxena, Shailendra.

In: Annals of Pharmacotherapy, Vol. 45, No. 9, 09.2011.

Research output: Contribution to journalArticle

Traut, Jamie L. ; MacDonald, Erin S. ; Spangler, Mikayla L. ; Saxena, Shailendra. / Montelukast for symptom control of interstitial cystitis. In: Annals of Pharmacotherapy. 2011 ; Vol. 45, No. 9.
@article{11f1476f4cc3478cb795f34412857c0a,
title = "Montelukast for symptom control of interstitial cystitis",
abstract = "OBJECTIVE: To describe the effects of montelukast, a leukotriene receptor antagonist commonly used in the treatment of allergic rhinitis and asthma, on the symptoms of interstitial cystitis (IC). CASE SUMMARY: A 64-year-old male had a history of IC with previous trials of solifenacin, dutasteride, and tamsulosin and little improvement in IC symptom reduction. When montelukast 10 mg was initiated for allergic rhinitis symptoms, a substantial improvement in urinary urgency and pain during therapy was noted. This improvement subsequently disappeared when montelukast was stopped. DISCUSSION: IC, a rare occurrence in the male population, is related to an inflammatory process and has also been associated with inappropriate leukotriene release, which is the target of montelukast therapy. In general, treatment for IC includes systemic medical therapy, local bladder treatment, surgical and neurosurgical procedures, and intravesical drug installation. Currently, montelukast is Food and Drug Administration approved for use in the treatment and prevention of mild-to-moderate asthma and exercise-induced asthma, as well as treatment of seasonal and perennial allergic rhinitis. While montelukast treatment did not cure the patient's IC, it improved his quality of life through substantial symptomatic relief, including less pain and urgency. CONCLUSIONS: Montelukast may be an effective treatment option in the management of interstitial cystitis. Further research is needed to substantiate this novel use.",
author = "Traut, {Jamie L.} and MacDonald, {Erin S.} and Spangler, {Mikayla L.} and Shailendra Saxena",
year = "2011",
month = "9",
doi = "10.1345/aph.1Q130",
language = "English",
volume = "45",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Montelukast for symptom control of interstitial cystitis

AU - Traut, Jamie L.

AU - MacDonald, Erin S.

AU - Spangler, Mikayla L.

AU - Saxena, Shailendra

PY - 2011/9

Y1 - 2011/9

N2 - OBJECTIVE: To describe the effects of montelukast, a leukotriene receptor antagonist commonly used in the treatment of allergic rhinitis and asthma, on the symptoms of interstitial cystitis (IC). CASE SUMMARY: A 64-year-old male had a history of IC with previous trials of solifenacin, dutasteride, and tamsulosin and little improvement in IC symptom reduction. When montelukast 10 mg was initiated for allergic rhinitis symptoms, a substantial improvement in urinary urgency and pain during therapy was noted. This improvement subsequently disappeared when montelukast was stopped. DISCUSSION: IC, a rare occurrence in the male population, is related to an inflammatory process and has also been associated with inappropriate leukotriene release, which is the target of montelukast therapy. In general, treatment for IC includes systemic medical therapy, local bladder treatment, surgical and neurosurgical procedures, and intravesical drug installation. Currently, montelukast is Food and Drug Administration approved for use in the treatment and prevention of mild-to-moderate asthma and exercise-induced asthma, as well as treatment of seasonal and perennial allergic rhinitis. While montelukast treatment did not cure the patient's IC, it improved his quality of life through substantial symptomatic relief, including less pain and urgency. CONCLUSIONS: Montelukast may be an effective treatment option in the management of interstitial cystitis. Further research is needed to substantiate this novel use.

AB - OBJECTIVE: To describe the effects of montelukast, a leukotriene receptor antagonist commonly used in the treatment of allergic rhinitis and asthma, on the symptoms of interstitial cystitis (IC). CASE SUMMARY: A 64-year-old male had a history of IC with previous trials of solifenacin, dutasteride, and tamsulosin and little improvement in IC symptom reduction. When montelukast 10 mg was initiated for allergic rhinitis symptoms, a substantial improvement in urinary urgency and pain during therapy was noted. This improvement subsequently disappeared when montelukast was stopped. DISCUSSION: IC, a rare occurrence in the male population, is related to an inflammatory process and has also been associated with inappropriate leukotriene release, which is the target of montelukast therapy. In general, treatment for IC includes systemic medical therapy, local bladder treatment, surgical and neurosurgical procedures, and intravesical drug installation. Currently, montelukast is Food and Drug Administration approved for use in the treatment and prevention of mild-to-moderate asthma and exercise-induced asthma, as well as treatment of seasonal and perennial allergic rhinitis. While montelukast treatment did not cure the patient's IC, it improved his quality of life through substantial symptomatic relief, including less pain and urgency. CONCLUSIONS: Montelukast may be an effective treatment option in the management of interstitial cystitis. Further research is needed to substantiate this novel use.

UR - http://www.scopus.com/inward/record.url?scp=80052444420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052444420&partnerID=8YFLogxK

U2 - 10.1345/aph.1Q130

DO - 10.1345/aph.1Q130

M3 - Article

VL - 45

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -